Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine and Hydromorphone for Acute Pain in Buprenorphine-Maintained Patients
NCT03933865Phase 1Terminated
- Sponsor
- University of California, San Francisco
- Start
- Oct 2018
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ketamine in acute pain, sponsored by University of California, San Francisco. Primary endpoint: Peak change in cold pressor tolerance at 1 day. Started Oct 2018; status: terminated.
02
Drugs
ketamine
03
Conditions
acute pain
Beyond the preview
Go deeper on NCT03933865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03933865.